(Q52938218)

9 May 2018

editorial

0 references

review article

1 reference

title

Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? (English)

1 reference

9 May 2018

1 reference

Saiama N Waqar

1

1 reference

9 May 2018

Daniel Morgensztern

series ordinal

2

1 reference

9 May 2018

publication date

7 June 2015

1 reference

9 May 2018

Expert Review of Clinical Immunology

published in

1 reference

9 May 2018

volume

11

1 reference

9 May 2018

issue

8

1 reference

9 May 2018

page(s)

871-873

1 reference

9 May 2018

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1054374

10.1586/1744666X.2015.1054374

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018